发热伴血小板减少综合征病毒：一种高致死性布尼亚病毒。
Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus.
机构信息
NHC Key Laboratory of Carcinogenesis, Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Department of Microbiology, School of Basic Medical Sciences, Central South University, Changsha, China.
出版信息
Crit Rev Microbiol. 2021 Feb;47(1):112-125. doi: 10.1080/1040841X.2020.1847037. Epub 2020 Nov 27.
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a novel bunyavirus. Since 2007, SFTS disease has been reported in China with high fatality rate up to 30%, which drew high attention from Centre for Disease Control and Prevention and government. SFTSV is endemic in the centra l and eastern China, Korea and Japan. There also have been similar cases reported in Vietnam. The number of SFTSV infection cases has a steady growth in these years. As SFTSV could transmitted from person to person, it will expose the public to infectious risk. In 2018 annual review of the Blueprint list of priority diseases, World Health Organisation has listed SFTSV infection as prioritised diseases for research and development in emergency contexts. However, the pathogenesis of SFTSV remains largely unclear. Currently, there are no specific therapeutics or vaccines to combat infections of SFTSV. This review discusses recent findings of epidemiology, transmission pathway, pathogenesis and treatments of SFTS disease.
严重发热伴血小板减少综合征病毒（SFTSV）是一种新型布尼亚病毒。自 2007 年以来，中国已报告出现严重发热伴血小板减少综合征疾病，其死亡率高达 30%，引起了疾病预防控制中心和政府的高度关注。SFTSV 在中国中部和东部、韩国和日本流行。越南也有类似病例报告。近年来，SFTSV 感染病例数量稳步增长。由于 SFTSV 可在人与人之间传播，因此会使公众面临感染风险。在 2018 年《传染病防治纲要》优先疾病年度审查中，世界卫生组织已将 SFTSV 感染列为紧急情况下研究和开发的优先疾病。然而，SFTSV 的发病机制仍不清楚。目前，尚无针对 SFTSV 感染的特效治疗方法或疫苗。本综述讨论了 SFTS 疾病的流行病学、传播途径、发病机制和治疗的最新发现。
Zotero 插件